



# Metabolomic Profile in Patients with Malignant Disturbances of the Prostate: An Experimental Approach

## *Perfil metabolómico en pacientes con alteraciones malignas de la próstata: Un enfoque experimental*

Herney Andrés García-Perdomo<sup>1</sup> Leidy Vanessa Mena Ramirez<sup>2</sup> Julien Wist<sup>3</sup> Adalberto Sanchez<sup>4</sup>

<sup>1</sup> Division of Urology/Uro-oncology, Department of Surgery, UROGIV Research Group, School of Medicine, Universidad del Valle, Cali, Colombia

<sup>2</sup> Department of Chemistry, Faculty of Natural and Exact Sciences, Universidad del Valle, Cali, Colombia

<sup>3</sup> Department of Chemistry, Faculty of Natural and Exact Sciences, DARMN Research Group, Universidad del Valle, Cali, Colombia

<sup>4</sup> Department of Physiological Sciences, LABIOMOL Research Group, School of Basic Sciences, Universidad del Valle, Cali, Colombia

**Address for correspondence** Herney Andrés García-Perdomo, MD MSc EdD PhD FACS, Grupo de Investigaciones UROGIV, División de Urología/Uroncología, Departamento de Cirugía, Escuela de Medicina, Universidad del Valle, calle 4B no 36-00, Cali, Colombia (e-mail: herney.garcia@correounivalle.edu.co).

Urol Colomb 2022;31(2):e73–e81.

### Abstract

**Purpose** To identify metabolites in humans that can be associated with the presence of malignant disturbances of the prostate.

**Methods** In the present study, we selected male patients aged between 46 and 82 years who were considered at risk of prostate cancer due to elevated levels of prostate-specific antigen (PSA) or abnormal results on the digital rectal examination. All selected patients came from two university hospitals (Hospital Universitario del Valle and Clínica Rafael Uribe Uribe) and were divided into 2 groups: cancer (12 patients) and non-cancer (20 patients). Cancer was confirmed by histology, and none of the patients underwent any previous treatment. Standard protocols were applied to all the collected blood samples. The resulting plasma samples were kept at -80°C, and a profile of each one was acquired by nuclear magnetic resonance (NMR) using established experiments. Multivariate analyses were applied to this dataset, first to establish the quality of the data and identify outliers, and then, to model the data.

**Results** We included 12 patients with cancer and 20 without it. Two patients were excluded due to contamination with ethanol. The remaining ones were used to build an Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) model (including 15 non-cancer and 10 cancer patients), with acceptable discrimination ( $Q^2 = 0.33$ ). This model highlighted the role of lactate and lipids, with a positive association of these two metabolites and prostate cancer.

### Keywords

- ▶ prostate neoplasm
- ▶ metabolomics
- ▶ prostate cancer
- ▶ lactate
- ▶ nuclear magnetic resonance

received  
September 9, 2021  
accepted  
January 20, 2022

DOI <https://doi.org/10.1055/s-0042-1744253>.  
ISSN 0120-789X.  
e ISSN 2027-0119.

© 2022. Sociedad Colombiana de Urología. All rights reserved.  
This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (<https://creativecommons.org/licenses/by-nc-nd/4.0/>)  
Thieme Revinter Publicações Ltda., Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

## Resumen

### Palabras clave

- ▶ neoplasia de la próstata
- ▶ metabolómica
- ▶ cáncer de próstata
- ▶ lactato
- ▶ resonancia magnética

**Conclusiones** The primary discriminative metabolites between patients with and without prostate cancer were lactate and lipids. These might be the most reliable biomarkers to trace the development of cancer in the prostate.

**Objetivo** Identificar metabolitos en humanos que pueden estar asociados con la presencia de alteraciones malignas de la próstata.

**Métodos** Se incluyeron muestras de pacientes masculinos entre 46 y 82 años y que se consideraron en riesgo de cáncer de próstata debido a la elevación del antígeno prostático específico (PSA) o el examen rectal anormal. Todos los pacientes seleccionados procedían de dos hospitales universitarios (Hospital Universitario del Valle y Clínica Rafael Uribe Uribe) y se dividieron en dos grupos: Oncológicos (12) vs no oncológicos (20). El cáncer fue confirmado por histología, y ninguno de ellos recibió tratamiento previo. Se aplicaron protocolos estándar a todas las muestras de sangre recolectadas. Las muestras de plasma resultantes se mantuvieron a  $-80^{\circ}\text{C}$  y se adquirió un perfil de cada muestra mediante RMN. Se aplicaron análisis multivariantes a este conjunto de datos, primero para establecer la calidad de los datos e identificar valores atípicos, y para modelar los datos.

**Resultados** Se incluyeron 12 pacientes con cáncer y 20 pacientes sin cáncer. Dos pacientes fueron excluidos por contaminación con etanol. Los restantes se utilizaron para construir un modelo OPLS-DA (15 pacientes no oncológicos y diez oncológicos), con una discriminación aceptable ( $Q^2 = 0,33$ ). Este modelo destacó el papel del lactato y los lípidos, encontrando una asociación positiva entre estos dos metabolitos y el cáncer de próstata.

**Conclusiones** Los principales metabolitos discriminativos entre pacientes con cáncer de próstata versus no cáncer fueron el lactato y los lípidos. Estos podrían ser los biomarcadores más confiables para rastrear el desarrollo del cáncer en la próstata.

## Introduction

Prostate cancer (PCa) is the second most frequent malignant neoplasia diagnosed in men (mainly in those aged  $> 65$  years) in both developing and developed countries after skin cancer), and it is one of the leading causes of cancer death.<sup>1-3</sup> A public health concern in developed countries, in which older adults account for the most significant proportion of the population,<sup>4</sup> PCa is a heterogeneous disease with a variable natural history. It may display latency periods of up to 20 years in which it remains confined to the organ. Although prostate cancer lesions can remain localized for long periods, more aggressive forms may occur. When metastasis occurs, the lymph nodes and bones are predominantly affected, with detrimental results.<sup>5</sup> Patients with high risk and susceptibility to develop PCa require recurrent screening over time, with age, ethnicity, and family history being the most important risk factors.<sup>6</sup>

Concerns were raised about the diagnosis and early treatments of this disease due to the absence of specific markers.<sup>7</sup> To date, the gold standard for the diagnosis of PCa is an invasive procedure consisting of a histopathological evaluation of the prostate, a procedure with significant morbidity.<sup>8</sup> Currently, the use of the prostate-specific antigen (PSA) as a screening and monitoring marker for PCa is widespread<sup>9</sup>,

but there is still a debate about how to screen for PCa among men in the overall population. The PSA is prostate-specific, but it has a low specificity and could also increase unnecessary biopsies without lowering mortality.<sup>10</sup>

In the search for new biomarkers, metabolomics is the established ‘-omics’ family. It measures the systemic activity and conditions in the human body and suggests that metabolism dysregulation plays a fundamental role in the development and progression of common conditions and malignancies.<sup>11</sup>

Specifically, the metabolism of prostate cells the components of the prostatic fluid, such as PSA, spermine, myoinositol, and citrate (with higher levels than in any other organ). In PCa, cells lose the ability to accumulate citrate by lowering the levels of zinc.<sup>11</sup> Additionally, there is evidence that chronic inflammation and related markers like metabolic syndrome increase tumor growth.<sup>12</sup>

Metabolomics employs different techniques to identify biomolecules.<sup>13</sup> So far, the most promising biomarkers identified for the diagnosis of PCa, through high-throughput liquid and gas chromatography-tandem mass spectrometry and high-resolution magic-angle-spinning proton magnetic resonance spectroscopy in plasma, urine, and tissue are sarcosine (area under the curve [AUC]: 0.67),<sup>14</sup> choline, phosphocholines (AUC: 0.982),<sup>15</sup> phosphorylcholines, carnitines (AUC: 0.97),<sup>16</sup>

citrate (AUC: 0.89),<sup>17</sup> amino acids (lysine, glutamine, and ornithine),<sup>18–21</sup> arachidonoyl amine (AUC: 0.86)<sup>16</sup> and lysophospholipids (steroid hormone biosynthesis pathway and bile acids – sensitivity: 92%; specificity: 94%).<sup>20</sup>

The present study aimed to identify the metabolites associated with patients with malignant prostate disturbances compared with non-cancer patients.

## Methods

The present is an observational study. Two populations were sampled from a pool of male candidates at risk of PCA considering their elevated PSA or abnormal result on the digital rectal examination. Group 1 was composed of patients with localized PCA who were characterized according to the risk classification, and group 2 consisted of patients with prostate biopsy negative for malignancy. All samples were taken from patients in the Urology Section of Hospital Universitario del Valle and the Prostate Biopsy Section of Clínica Rafael Uribe Uribe, in Cali, Colombia.

### Exclusion Criteria

Patients were excluded when the following conditions were found: other concomitant cancer types, coagulation disorders, and renal or metabolic disorders such as diabetes mellitus, gout, or hyperthyroidism. Additionally, patients were excluded if they had symptoms of acute diseases two weeks before the sample collection, such as a febrile episode, cough, headache, diarrhea, hematuria, and psychic disorders or episodes of traumatic stress. Ingestion of medications up to two weeks before the collection of samples, such as antibiotics, hormones, non-steroidal anti-inflammatory drugs, as well as the performance of chemotherapy or radiotherapy also led to exclusion.

### Collection of Samples and Sample Size

Sampling was performed by convenience and according to the availability of the patients admitted to each hospital. They were instructed and requested to sign an informed consent form prior to providing the samples. Each patient was informed about the risks and benefits of both the procedure and the research project. The patients provided a blood sample and were submitted to the standard prostate biopsy procedure to confirm the diagnosis.

### Handling Samples

#### Blood Sampling Procedure

The procedure was performed by staff trained in sampling in humans. After the collection, the blood was mixed by manual rotation of the tube for 8 to 10 times. It was stored in vacutainer tubes (collection tubes with ethylenediaminetetraacetic acid [EDTA]) vertically at 4°C until centrifugation. The samples were transported within two hours of the collection.

#### Procedure for Separating the Plasma

Prior to the centrifugation, the centrifuge was allowed to cool to 4°C. Previously, an aliquot of 500 µL of phosphate buffer

with a pH of 7.4 (0.142M of Na<sub>2</sub>HPO<sub>4</sub>) was taken in 1.5 mL Eppendorf (Eppendorf AG, Hamburg, Germany) tubes.

The blood samples were centrifuged at 4°C in a rotor (oscillating head) for 5 minutes at 4,000 rpm. After centrifugation, 250 µL of the plasma layer was taken with an appropriate micropipette without disturbing the buffy coat layer, and it was stored in a -80°C biofreezer.

### Preparation for Resonance

Each sample was thawed at room temperature and centrifuged at 12,000 g at 4°C for 5 minutes. A total of 65 µL of phosphate buffer with a pH of 7.4 (0.142M Na<sub>2</sub>HPO<sub>4</sub>), prepared with D<sub>2</sub>O and 3-(trimethylsilyl)propionic-2,2,3,3-d<sub>4</sub> acid sodium salt (TSP), and 585 µL of the sample were added. The sample was centrifuged again at 12,000 g at 4°C for 5 minutes. Finally, 600 µL of supernatant was transferred to a 5-mm nuclear magnetic resonance (NMR) tube.

Proton nuclear magnetic resonance (<sup>1</sup>H-NMR) spectra were acquired on the Bruker Avance II Ultra Shield 400 MHz spectrometer (Bruker BioSpin, Rheinstetten, Germany) with a direct broadband observe (BBO) probe equipped with 3 gradients at a temperature of 300° K. The temperature regulation of the probe head was calibrated using pure methanol samples. The final spectra were obtained using a standard Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence, and 64 scans were accumulated. The observed window was of 12 ppm, and the relaxation delay was of 4 seconds. Presaturation of the water signal was necessary to attenuate the intense signal of the solvent. The CPMG block in the pulse sequence enables the removal from the spectrum of signals belonging to molecules of high molecular weight, improving the baseline quality. Prior to each acquisition, the resonance frequency and the homogeneity of the magnetic field were adjusted automatically, while calibration of the solvent suppression was performed manually. The spectra were referenced concerning the resonance of the α-glucose doublet at δ 5.233 ppm, since it is known that TSP can aggregate with the proteins present in the sample.<sup>22</sup>

### Data Analysis

The resulting data matrix was preprocessed using the R (R Foundation for Statistical Computing, Vienna, Austria) software.<sup>23</sup> First, a baseline correction was applied. Then, the TSP regions, and the water and anticoagulant signals were cut from the spectrum. Second, binning and Pareto scaling were performed for the remaining spectrum between δ 0.1 ppm and 6.0 ppm. Third, principal component analysis (PCA) was performed to inspect the data quality and highlight outliers visually; then, Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) was applied. Accordingly, metabolites were identified with the support of statistical total correlation spectroscopy (STOCSY) analysis.

### Ethics

The present study fulfils all international ethical requirements for research in humans, and was approved by the Institutional Review Board at Universidad del Valle.

## Results

We collected plasma samples from 32 patients admitted upon suspicion of PCa; 12 patients were confirmed positive, while the remaining 20 were not. The median age of the

sample was of 69.5 years, ranging from 46 to 82 years. All patients confirmed positive had localized PCa with no evidence of metastasis in further studies (►Table 1). After collecting the samples, acquiring the profiles, and referencing glucose, 12 metabolites were assigned according to the


**Table 1** Characteristics of the study sample

| Age                                     | Ethnicity   | Setting                   | History                   | Urethral catheter | PSA   | Histology   | Tumor | ISUP | Risk group   |
|---|-------------|---------------------------|---------------------------|-------------------|-------|---|-------|------|--------------|
| <b>Patients with Cancer</b>             |             |                           |                           |                   |       |   |       |      |              |
| 57                                      | Black       | Cali                      | No                        | No                | 8.01  | Acinar adenocarcinoma   | T2a   | 1    | Low          |
| 74                                      | Multiethnic | Sabaneta                  | No                        | No                | 9.05  | Acinar adenocarcinoma   | T2a   | 1    | Low          |
| 61                                      | Multiethnic | Cali                      | No                        | No                | 15.3  | Acinar adenocarcinoma   | T1c   | 1    | Intermediate |
| 67                                      | Black       | Tumaco                    | No                        | No                | 11.2  | Acinar adenocarcinoma   | T2a   | 1    | Intermediate |
| 60                                      | Black       | Puerto Tejada             | No                        | No                | 14.82 | Acinar adenocarcinoma   | T2a   | 1    | Intermediate |
| 78                                      | Multiethnic | Cali                      | No                        | No                | 20.2  | Acinar adenocarcinoma   | T2a   | 1    | High         |
| 82                                      | Black       | Zarzal                    | No                        | No                | 16.61 | Acinar adenocarcinoma   | T2c   | 1    | High         |
| 74                                      | Multiethnic | Popayán                   | No                        | No                | 15.99 | Acinar adenocarcinoma   | T2c   | 1    | High         |
| 65                                      | Multiethnic | Santander de Quilichao    | No                        | No                | 7.08  | Acinar adenocarcinoma   | T2c   | 1    | High         |
| 82                                      | Multiethnic | Cali                      | No                        | No                | 13.74 | Acinar adenocarcinoma   | T2a   | 4    | High         |
| 77                                      | Multiethnic | Silvia                    | No                        | Yes               | 75.85 | Acinar adenocarcinoma   | T2c   | 3    | High         |
| 63                                      | Multiethnic | Cali                      | No                        | No                | 20.9  | Acinar adenocarcinoma   | T2c   | 2    | High         |
| <b>Included patients without Cancer</b> |             |                           |                           |                   |       |   |       |      |              |
| 75                                      | Multiethnic | Cali                      | No                        | No                | 4.88  | Negative for malignancy   |       |      |              |
| 54                                      | Multiethnic | Cali                      | No                        | No                | 10.1  | Negative for malignancy   |       |      |              |
| 60                                      | Multiethnic | Cali                      | No                        | No                | 8     | Negative for malignancy   |       |      |              |
| 73                                      | Multiethnic | Pradera                   | No                        | Yes               | 38    | Negative for malignancy   |       |      |              |
| 51                                      | Multiethnic | Cali                      | No                        | No                | 4.24  | Chronic prostatitis   |       |      |              |
| 72                                      | Multiethnic | Cali                      | No                        | No                | 5.25  | Chronic prostatitis   |       |      |              |
| 64                                      | Multiethnic | Santander de Quilichao    | No                        | No                | 3.12  | Benign prostatic tissue/<br>Chronic prostatitis (IHC)                               |       |      |              |
| 77                                      | Multiethnic | Cali                      | No                        | No                | 11.3  | Benign hyperplasia/Chronic<br>prostatitis/Glandular<br>atrophy/Atypical acini       |       |      |              |
| 54                                      | Black       | Cali                      | One relative<br>with Pca  | No                | 12.16 | Chronic prostatitis/<br>Glandular atrophy (IHC)                                     |       |      |              |
| 70                                      | Multiethnic | Pradera                   | Two relatives<br>with Pca | No                | 10.8  | Glandular atrophy (IHC)   |       |      |              |
| 66                                      | Multiethnic | Palmira                   | No                        | No                | 6.63  | Glandular atrophy (IHC)   |       |      |              |
| 65                                      | Multiethnic | Cali                      | No                        | No                | 4.37  | Atypical acinar proliferation/<br>Glandular atrophy (IHC)                           |       |      |              |
| 77                                      | Multiethnic | Cali                      | No                        | Yes               | 10.57 | Atypical acinar proliferation/<br>Glandular atrophy (IHC)                           |       |      |              |
| 73                                      | Multiethnic | Cali                      | No                        | No                | 8.4   | High-grade prostatic<br>intraepithelial neoplasia (IHC)                             |       |      |              |
| 73                                      | Multiethnic | Cajibío                   | No                        | No                | 8.61  | Glandulostromal hyperplasia/<br>Chronic prostatitis/<br>Glandular atrophy           |       |      |              |
| 69                                      | Multiethnic | Cisneros,<br>Juntas Dagua | No                        | No                | 5.07  | Glandulostromal hyperplasia/<br>Chronic prostatitis/<br>Glandular atrophy           |       |      |              |
| 73                                      | Multiethnic | Restrepo                  | One relative<br>with Pca  | No                | 6.85  | Benign hyperplasia/<br>Chronic prostatitis/<br>Glandular atrophy/<br>Atypical acini |       |      |              |

**Table 1** (Continued)

| Age | Ethnicity   | Setting | History | Urethral catheter | PSA  | Histology   | Tumor | ISUP | Risk group |
|-----|-------------|---------|---------|-------------------|------|---|-------|------|------------|
| 46  | Multiethnic | Dagua   | No      | No                | 19   | Glandulostromal Hyperplasia/<br>Acute and chronic prostatitis/<br>Glandular atrophy |       |      |            |
| 71  | Multiethnic | Cali    | No      | No                | 11   | Glandulostromal hyperplasia/<br>Acute and chronic prostatitis/<br>Glandular atrophy |       |      |            |
| 69  | Multiethnic | Palmira | No      | No                | 9.55 | Glandulostromal hyperplasia/<br>Acute and chronic prostatitis/<br>Glandular atrophy |       |      |            |

Abbreviations: IHC, immunohistochemistry; ISUP, International Society of Urological Pathology grading. PCa, prostate cancer; PSA, prostate-specific antigen.



**Fig. 1** <sup>1</sup>H-NMR-based metabolomic profile of a sample of healthy human plasma.

study by Barton et al.<sup>24</sup> The metabolomic profile of a sample of healthy human plasma is displayed in ►Fig. 1.

### Principal Component Analysis

Four samples were located outside the confidence interval of the PCA models. Three corresponded to samples with an intense signal of ethanol (two healthy and one with cancer), indicating probable contamination during recollection, while one sample (of a cancer patient) had an intense lipid signal.

The resulting PCA model (►Fig. 2a) explains more than 50% of the variance with just two components. Two groups emerged, showing that the data contained discriminant information. ►Fig. 2b displays the same model but colored according to the risk of progression measured by the D'amico classification. Patients with a high risk of progression were found more condensed, which was expected despite the low number of samples.

### Subgroup by the Risk of Progression Analysis

Although the sample of the present study was small, we can show that the most critical and discriminative samples with cancer have a high risk of progression. Accordingly, the patients with low and intermediate risks are apart from this group of patients (►Fig. 2d).

### OPLS-DA Model

The same profiles were used to build a supervised model analysis. The OPLS-DA was chosen for its wide acceptance

and ease of interpretation. We applied the 5-fold method to 15 non-cancer patients and 10 patients with cancer, which resulted in a discriminative expression of both groups ( $R^2 = 0.5902$ ;  $Q^2 = 0.3302$ ; ►Fig. 3a). Additionally, we described the loadings plot to identify the metabolites associated with cancer (►Fig. 3b and ►Fig. 3c).

The metabolites associated with PCa were shown in the 1D graph of the STOCSY analysis to discriminate metabolites better. ►Fig. 4a shows loading 657 (lipids), and ►Fig. 4b, loading 647 (lactate), which were found to be positively associated with PCa.

## Discussion

### Summary of the Main Results


According to the PCA, there was a consistent difference between the two groups of patients, mainly regarding the high risk of progression in PCa patients. The two essential metabolites that discriminate patients with and without PCa were lactate and lipids in plasma samples.

### Contrast with the Literature


In 1920, it was described that cancer cells, even in the presence of oxygen, produce adenosine triphosphate (ATP) through the anaerobic pathway (anaerobic glycolysis) instead of the tricarboxylic acid cycle (Krebs cycle). The Warburg effect consists of the ability to sustain high rates of glycolysis for the generation of ATP.<sup>25</sup> In prostatic epithelial cells, we find an overexpression of zinc-regulated transporter/iron-regulated transporter-like protein 1 (ZIP1), which inhibits mitochondrial aconitase (m-aconitase) in the tricarboxylic acid cycle. This leads to an accumulation of citrate in the healthy prostate.<sup>26</sup> In PCa, the concentration of ZIP1 lowers, since the malignant tissue cannot accumulate zinc. Therefore, anaerobic glycolysis increases, overproducing lactate. This process might herald the early development of PCa, even before it affects histology.<sup>26</sup>

Thus, lactate has been associated with the progression of the tumor and with pyruvate and alanine. As a pathway modulator, lactate has been studied as a urine biomarker for the non-invasive detection of PCa. Nonetheless, there are no consistent results among studies.<sup>27</sup>


## a. Healthy patients (16 samples).




## c. Cancer and non-cancer patients



## b. Cancer patients (10 samples)



## d. Showing the risk of progression



**Fig. 2** Principal component analysis: a. Healthy patients, b. Cancer patients, c. Cancer and non-cancer patients and d. Risk of progression.

There is an essential difference in PCa regarding glucose metabolism due to androgen receptor (AR) signaling. It has been described that glycolysis differs between cells sensitive (early stages) and non-sensitive (advanced) to androgen.<sup>27,28</sup> The androgen receptor also regulates the activity of several genes related to glucose consumption, such as *hexokinase-2 (HKII)*, *pentose phosphate pathway (PPP)*, and *calcium/calmodulin-dependent protein kinase  $\beta$  (CaMKK $\beta$ )*, among others. Overall, the AR stimulates glycolysis and anabolic metabolism.<sup>27</sup>


Regarding metabolomics, we present an experiment based on plasma samples and NMR, which is broadly accepted in literature and could be used in a clinical environment. Plasma offers several advantages, such as the fact that it is easier to obtain, presents fewer diurnal variations, and is less invasive than a prostate biopsy. On the other hand, sample preparation is more tedious than that of urine, and the plasma contains a higher concentration of proteins.<sup>26</sup>

Our results indicate a dysregulation in the energetics pathway according to the differences in lactate and lipids between the groups. Other studies<sup>29</sup> describing the use of <sup>1</sup>H-NMR in plasma samples found, on the one hand, in-

creased levels of alanine, pyruvate, and sarcosine, and lower levels of glycine, associated with disturbances in energetic metabolism and lipogenesis, and alterations in glycine synthesis and degradation. On the other hand, lower levels were reported for acylcarnitines, Choline, and arginine due to alterations in the metabolism of fatty acids, the phospholipid membrane, and amino acids.<sup>30</sup>

Other studies<sup>19,31-33</sup> relying on different analytical techniques (liquid and gas chromatography-tandem mass spectrometry) have found similar results with different biomarkers: alterations in lipid metabolism, disturbances in growth inhibition and induction of apoptosis, and alterations in amino acid and energetic metabolism (increased levels of palmitic acid, linolenic acid, aspartic acid, choline, alanine, lysine, sarcosine, and phosphatidylcholine, and low levels of ornithine, stearic acid, glutamine, valine, tryptophan, dehydroepiandrosterone (DHEAS), epiandrosterone sulfate, carnitines, 2-hydroxybutyrate, and ketone bodies, among others).

Authors worldwide have evaluated a plethora of biomarker candidates for the diagnosis and prognosis of PCa patients. In the blood, the most relevant biomarker for diagnosis are



**Fig. 3** OPLS-DA and loadings plots.


citrate, glycine, glycerol-3-phosphate, and alanine; and, regarding prognosis, citrate and alanine.<sup>34</sup>

Eidelman et al.<sup>35</sup> and Andersen et al.<sup>36</sup> consider the metabolomic profile a trending topic in PCa research. They have also reported citrate/zinc, lactate, glutamine, arginine, lipids, and other critical metabolic pathways as vital for the development of better diagnostic methods and treatment options for PCa patients. These all are considered part of the metabolic phenotype of PCa.<sup>35,36</sup> As aforementioned, other key metabolites are essential when differentiating patients with and without cancer, such as phosphocholine, glutamate, hypoxanthine, arginine, and alfa-glucose. Tumor aggressiveness, which is also essential in the decision-making

process, must also be considered.<sup>37</sup> Nonetheless, it is essential to consider that none of these tools are currently available for use in clinical practice.

#### **Strengths and Limitations**

The present is the first observational study conducted in Colombia for the early identification of biomarkers in localized PCa through metabolomics. We implemented a method to analyze the samples through NMR and found exciting results to better understand the pathophysiology of PCa. The validation of lactate and lipids as biomarkers might be performed through studies with a larger population to extrapolate results, so that the use of these metabolites



**Fig. 4** STOCYSY 1D graphs.

and this technique may be considered as a method for early screening or to diagnose PCa.

Regarding the limitations, we found the following to be considered in the subsequent trials: low sample size and the lack of association with mass spectrometry (MS) to complement and identify low-weight molecules (lipidomics).

## Conclusions

The main differences between patients with and without PCa regarding their metabolomics profiles confirmed that lactate and lipids are the most reliable biomarkers to track the development of cancer in the prostate.

We suggest continuing research in metabolomics to elucidate what happens in the prostate when malignant disturbances present.

## Funding

This work was supported by the Colombian Ministry of Science, Technology and Innovation RC. No. 873-2019 Project code: 1106-844-67709

## Conflict of interests

The authors have no conflict of interests to declare.

## References

- 1 Wu X, Gu J. Heritability of prostate cancer: a tale of rare variants and common single nucleotide polymorphisms. *Ann Transl Med* 2016;4(10):206–209
- 2 Packer JR, Maitland NJ. The molecular and cellular origin of human prostate cancer. *Biochim Biophys Acta* 2016;1863(6 Pt A):1238–1260
- 3 Rand KA, Rohland N, Tandon A, et al; African Ancestry Prostate Cancer GWAS Consortium ELLIPSE/GAME-ON Consortium. Whole-exome sequencing of over 4100 men of African ancestry and prostate cancer risk. *Hum Mol Genet* 2016;25(02):371–381
- 4 Mottet (Chair) N, Bellmunt J, Briers (Patient Representative) E, Bolla M, Cornford (Vice-chair) P, De Santis M, et al. Guidelines on Prostate Cancer [Internet]. Vol. 53; European Association of Urology; 2017. Available from: [http://www.uroweb.org/fileadmin/tx\\_eauguidelines/2005/Pocket/Prostate\\_Cancer.pdf](http://www.uroweb.org/fileadmin/tx_eauguidelines/2005/Pocket/Prostate_Cancer.pdf)
- 5 Wang Z-Y, Li H-Y, Jiang Z, Zhou T-B, Drummen GPC. GSTM1 Gene Polymorphism is Implicated in Increased Susceptibility to Prostate Cancer in Caucasians and Asians. *Technol Cancer Res Treat* 2016;15(06):NP69–NP78
- 6 Helfand BT, Kearns J, Conran C, Xu J. Clinical validity and utility of genetic risk scores in prostate cancer. *Asian J Androl* 2016;18(04):509–514
- 7 Dimitriadis E, Kalogeropoulos T, Velaeti S, et al. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer. *Anticancer Res* 2013;33(01):191–197
- 8 Leyten GH, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. *Eur Urol* 2014;65(03):534–542
- 9 Salami SS, Schmidt F, Laxman B, et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. *Urol Oncol* 2013;31(05):566–571
- 10 Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. *Cochrane Database Syst Rev* 2013;1(01):CD004720
- 11 Kelly RS, Vander Heiden MG, Giovannucci E, Mucci LA. Metabolomic biomarkers of prostate cancer: Prediction, diagnosis, progression, prognosis, and recurrence. *Cancer Epidemiol Biomarkers Prev* 2016;25(06):887–906
- 12 Hsing AW, Sakoda LC, Chua S Jr. Obesity, metabolic syndrome, and prostate cancer. *Am J Clin Nutr* 2007;86(03):s843–s857
- 13 Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. *Clin Cancer Res* 2009;15(02):431–440
- 14 Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. *Nature* 2009;457(7231):910–914
- 15 Cheng LL, Burns MA, Taylor JL, et al. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. *Cancer Res* 2005;65(08):3030–3034
- 16 Likhov PG, Dashtiev MI, Moshkovskii SA, Archakov AI. Metabolite profiling of blood plasma of patients with prostate cancer. *Metabolomics* 2010;6(01):156–163
- 17 Serkova NJ, Gamito EJ, Jones RH, et al. The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. *Prostate* 2008;68(06):620–628



- 18 Osl M, Dreiseitl S, Pfeifer B, et al. A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry. *Bioinformatics* 2008;24(24):2908–2914
- 19 Miyagi Y, Higashiyama M, Gochi A, et al. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. *PLoS One* 2011;6(09):e24143 [http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed10&AN=2011500697%5Cnhttp://imp-primo.hosted.exlibrisgroup.com/openurl/44IMP/44IMP\\_services\\_page?sid=OVID&isbn=&issn=1932-6203&volume=6&issue=9&date=2011&title=PLoS+ONE&atitle=Plasma+](http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed10&AN=2011500697%5Cnhttp://imp-primo.hosted.exlibrisgroup.com/openurl/44IMP/44IMP_services_page?sid=OVID&isbn=&issn=1932-6203&volume=6&issue=9&date=2011&title=PLoS+ONE&atitle=Plasma+) [Internet]
- 20 Zang X, Jones CM, Long TQ, et al. Feasibility of detecting prostate cancer by ultraperformance liquid chromatography-mass spectrometry serum metabolomics. *J Proteome Res* 2014;13(07):3444–3454
- 21 Struck-Lewicka W, Kordalewska M, Bujak R, et al. Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study. *J Pharm Biomed Anal* 2015;111:351–361
- 22 Pearce JTM, Athersuch TJ, Ebbels TMD, Lindon JC, Nicholson JK, Keun HC. Robust algorithms for automated chemical shift calibration of 1D 1H NMR spectra of blood serum. *Anal Chem* 2008;80(18):7158–7162
- 23 R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2017. Available from: <https://www.r-project.org/>
- 24 Barton RH, Waterman D, Bonner FW, et al; Procardis Consortium. The influence of EDTA and citrate anticoagulant addition to human plasma on information recovery from NMR-based metabolic profiling studies. *Mol Biosyst* 2010;6(01):215–224
- 25 Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. *Cell* 2008;134(05):703–707
- 26 Lima AR, Bastos Mde L, Carvalho M, Guedes de Pinho P. Biomarker discovery in human prostate cancer: An update in metabolomics studies. *Transl Oncol* 2016;9(04):357–370. Doi: 10.1016/j.tranon.2016.05.004
- 27 Gonzalez-Menendez P, Hevia D, Mayo J, Sainz R. The dark side of glucose transporters in prostate cancer: Are they a new feature to characterize carcinomas? *Int J Cancer* 2018;142(12):2414–2424
- 28 Vaz CV, Alves MG, Marques R, et al. Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile. *Int J Biochem Cell Biol* 2012;44(11):2077–2084
- 29 Kumar D, Gupta A, Mandhani A, Sankhwar SN. Metabolomics-derived prostate cancer biomarkers: fact or fiction? *J Proteome Res* 2015;14(03):1455–1464
- 30 Giskeødegård GF, Hansen AF, Bertilsson H, et al. Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia. *Br J Cancer* 2015;113(12):1712–1719
- 31 Johansson M, Van Guelpen B, Vollset SE, et al. One-carbon metabolism and prostate cancer risk: prospective investigation of seven circulating B vitamins and metabolites. *Cancer Epidemiol Biomarkers Prev* 2009;18(05):1538–1543
- 32 Crowe FL, Allen NE, Appleby PN, et al. Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition. *Am J Clin Nutr* 2008;88(05):1353–1363
- 33 Saylor PJ, Karoly ED, Smith MR. Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer. *Clin Cancer Res* 2012;18(13):3677–3685
- 34 Kdadra M, Höckner S, Leung H, Kremer W, Schiffer E. Metabolomics Biomarkers of Prostate Cancer: A Systematic Review. *Diagnostics (Basel)* 2019;9(01):E21
- 35 Eidelman E, Twum-Ampofo J, Ansari J, Siddiqui MM. The metabolic phenotype of prostate cancer. *Front Oncol* 2017;7(JUN):131
- 36 Andersen MK, Giskeødegård GF, Tessem MB. Metabolic alterations in tissues and biofluids of patients with prostate cancer. *Curr Opin Endocr Metab Res* 2020;10:23–28
- 37 Dudka I, Thysell E, Lundquist K, et al. Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status. *BMC Cancer* 2020;20(01):437–453